Adenoid cystic carcinoma of breast: Recent advances

Table 1 Clinical characteristics of adenoid cystic carcinoma of the breast in recently reported cohorts

Ref.	No. of patients’		PathologicT1 or T2	Lymph nodeinvolvement	Distantmetastasis	Survival
	Cases	Age (yr)
Kulkarni et al[14]	933	60 (median)	Not reported	5.1%	Not reported	88% (5 yr)
Coates et al[15]	376	62 (mean)	90%	6.1%	1.1% (site not specified)	90% (10 yr)
Ghabach et al[11]	338	63 (mean)	95%	1.7%	< 1% (site not specified)	94.9% (10 yr)
Thompson et al[16]	244	62 (median)	92%	4.9%	2.9% (site not specified)	94.9% (10 yr)
Khanfir et al[17]	61	59 (median)	88%	0%	6.5% (bone, liver, lung)	94% (5 yr)
Defaud-Hénon et al[18]	30	61 (median)	95%	0%	10% (bone, liver, lung)	Not calculated
Vranic et al[19]	21	60.8 (mean)	85%	0%	20% (bone, kidney, lung)	90% (5 yr)

Table 2 Review of data reported on the expression of prognostic and predictive markers of breast adenoid cystic carcinoma (%)

Ref.	No. of cases	Percentage of cases showing positivity
		ER	PR	Her2
Kulkarni et al[14]	933	15	13	NA
Ghabach et al[11]	338	12	2	NA
Arpino et al[5]	28	46	36	NA
Mastropasqua et al[36]	20	15	10	0
Azouley et al[41]	18	0	0	0
Crisi et al[42]	6	0	0	0
Weigelt et al[43]	4	0	0	0

ER: Estrogen receptor; Her2: Human epidermal growth factor receptor 2; NA: Not available; PR: Progesterone receptor.

Table 3 Houston Methodist experience of adenoid cystic carcinoma of the breast (2004 to 2010)

Case No.	Age (yr)	Laterality	Tumor size (cm)	Perineural invasion	Lymph node metastasis	Distant metastasis	TMN stage (AJCC)	Follow-up (mo)
1	61	Left	1.6	-	pN0	-	IA	14
2	83	Right	3.0	-	pN0	Lungs, multiple	IV	85
3	51	Right	2.2	-	cN0	-	IIA	12
4	57	Left	4.5	+	cN0	-	IIA	65
5	48	Left	2.0	-	cN0	-	IIA	90

AJCC: American Joint Committee on Cancer.